These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28919803)

  • 1. Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease.
    Citera M; Freeman PR; Horowitz RI
    Int J Gen Med; 2017; 10():249-273. PubMed ID: 28919803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2.
    Horowitz RI; Freeman PR
    Healthcare (Basel); 2018 Nov; 6(4):. PubMed ID: 30400667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.
    Horowitz RI; Freeman PR
    Int J Gen Med; 2019; 12():101-119. PubMed ID: 30863136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome.
    Rebman AW; Bechtold KT; Yang T; Mihm EA; Soloski MJ; Novak CB; Aucott JN
    Front Med (Lausanne); 2017; 4():224. PubMed ID: 29312942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive clinical and laboratory evaluation of 224 patients with persistent symptoms attributed to presumed tick-bite exposure.
    Nilsson K; Skoog E; Jones V; Labbé Sandelin L; Björling C; Fridenström E; Edvinsson M; Mårtensson A; Olsen B
    PLoS One; 2021; 16(3):e0247384. PubMed ID: 33735220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of the Swiss guidelines on post-treatment Lyme disease syndrome.
    Nemeth J; Bernasconi E; Heininger U; Abbas M; Nadal D; Strahm C; Erb S; Zimmerli S; Furrer H; Delaloye J; Kuntzer T; Altpeter E; Sturzenegger M; Weber R; For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology
    Swiss Med Wkly; 2016; 146():w14353. PubMed ID: 27922168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-specific symptoms and post-treatment Lyme disease syndrome in patients with Lyme borreliosis: a prospective cohort study in Belgium (2016-2020).
    Geebelen L; Lernout T; Devleesschauwer B; Kabamba-Mukadi B; Saegeman V; Belkhir L; De Munter P; Dubois B; Westhovens R; ; Van Oyen H; Speybroeck N; Tersago K
    BMC Infect Dis; 2022 Sep; 22(1):756. PubMed ID: 36171561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling disease burden and Borrelia seroprevalence in Canadians with complex and chronic illness.
    Sanderson VP; Miller JC; Bamm VV; Tilak M; Lloyd VK; Singh-Ranger G; Wills MKB
    PLoS One; 2023; 18(11):e0291382. PubMed ID: 37939060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist.
    Wong KH; Shapiro ED; Soffer GK
    Clin Rev Allergy Immunol; 2022 Feb; 62(1):264-271. PubMed ID: 34687445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?
    Aucott JN; Rebman AW; Crowder LA; Kortte KB
    Qual Life Res; 2013 Feb; 22(1):75-84. PubMed ID: 22294245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.
    Horowitz RI; Fallon J; Freeman PR
    Microorganisms; 2024 Apr; 12(5):. PubMed ID: 38792737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.
    Horowitz RI; Freeman PR
    Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease.
    Fallon BA; Zubcevik N; Bennett C; Doshi S; Rebman AW; Kishon R; Moeller JR; Octavien NR; Aucott JN
    Front Med (Lausanne); 2019; 6():283. PubMed ID: 31867334
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome.
    Fitzgerald BL; Graham B; Delorey MJ; Pegalajar-Jurado A; Islam MN; Wormser GP; Aucott JN; Rebman AW; Soloski MJ; Belisle JT; Molins CR
    Clin Infect Dis; 2021 Oct; 73(7):e2342-e2349. PubMed ID: 32975577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure.
    Feng J; Li T; Yee R; Yuan Y; Bai C; Cai M; Shi W; Embers M; Brayton C; Saeki H; Gabrielson K; Zhang Y
    Discov Med; 2019 Mar; 27(148):125-138. PubMed ID: 30946803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium.
    Geebelen L; Lernout T; Kabamba-Mukadi B; Saegeman V; Sprong H; Van Gucht S; Beutels P; Speybroeck N; Tersago K
    Arch Public Health; 2017; 75():42. PubMed ID: 28794875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome?
    Adler BL; Chung T; Rowe PC; Aucott J
    Front Neurol; 2024; 15():1344862. PubMed ID: 38390594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease.
    Weitzner E; McKenna D; Nowakowski J; Scavarda C; Dornbush R; Bittker S; Cooper D; Nadelman RB; Visintainer P; Schwartz I; Wormser GP
    Clin Infect Dis; 2015 Dec; 61(12):1800-6. PubMed ID: 26385994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probable late lyme disease: a variant manifestation of untreated Borrelia burgdorferi infection.
    Aucott JN; Seifter A; Rebman AW
    BMC Infect Dis; 2012 Aug; 12():173. PubMed ID: 22853630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.